Reliance Life Sciences gets license for gene therapy technology from IIT Kanpur

10 Mar 2023 Evaluate

Reliance Life Sciences, part of the Promoter Group of Reliance Industries, has received license for gene therapy technology that has the potential to treat many hereditary eye diseases from The Indian Institute of Technology Kanpur. The gene therapy technology from IIT Kanpur will be further developed as an indigenous product by Reliance Life Sciences. Gene therapy using viral vectors has recently emerged as a potent tool in the field of molecular medicine. This is the first time that a gene therapy related technology has been developed and transferred from an academic institution to a company in India.

Reliance Life Sciences is a research-driven organization developing business opportunities in bio-therapeutics (plasma proteins, biosimilars and novel proteins), pharmaceuticals (later-generation, oncology generics), clinical research services, regenerative medicine (stem cells therapies) and molecular medicine.

Reliance Industries is India’s largest private sector company. The company’s activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and 4G digital services.

Reliance Industries Share Price

1540.90 2.50 (0.16%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Reliance Industries 1540.90
Indian Oil Corp. 163.80
BPCL 360.25
HPCL 450.30
MRPL 153.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×